Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

AML (Acute Myelogenous Leukemia): early-phase trial registry

1 of 2 indexed AML (Acute Myelogenous Leukemia) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

AML (Acute Myelogenous Leukemia): 2 US clinical trials tracked, 1 recruiting.

AML (Acute Myelogenous Leukemia) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Center for International Blood and Marrow Transplant Research, running 1 of these trials.

Enrollment posture brief

Registry condition aml-acute-myelogenous-leukemia

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%AML (this)50%
Open-enrollment share among volume-matched conditions near AML (Acute Myelogenous Leukemia)

AML (Acute Myelogenous Leukemia) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for AML (Acute Myelogenous Leukemia) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. AML (Acute Myelogenous Leukemia) is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on AML (Acute Myelogenous Leukemia) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Graft Manipulation (CD34+ Selection) Device
1 trials
Conditioning Regimen E Drug
1 trials
Conditioning Regimen D Drug
1 trials
Conditioning Regimen C Drug
1 trials
Conditioning Regimen B Drug
1 trials
Conditioning Regimen A Drug
1 trials

US sites by state

Facility locations filed on AML (Acute Myelogenous Leukemia) trials. A trial with sites in several states counts in each.

Washington 1 trials
Virginia 1 trials
Texas 1 trials
Oregon 1 trials
New York 1 trials
North Carolina 1 trials
Michigan 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this AML (Acute Myelogenous Leukemia) page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This AML (Acute Myelogenous Leukemia) condition card totals 2 registered trials; most-linked intervention Graft Manipulation (CD34+ Selection); top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.